Real-life contemporary vitamin K antagonist is still associated with very low time in therapeutic range despite strict international normalized ratio monitoring: Results of big data analysis.
INR
TTR
VKA
big data
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
14
12
2021
received:
21
10
2021
accepted:
16
02
2022
pubmed:
31
3
2022
medline:
25
8
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
This study aimed to determine the results of INR monitoring in patients on vitamin K antagonists (VKAs) and the time in therapeutic range (TTR) in 'real-world' settings. Retrospective analysis of 836,857 INR measurements performed in adults from February 2010 to August 2015 in two districts in the French Brittany region. Of the 836,857 INR measurements, 94.9% were ordered by general practitioners and 2.0% by cardiologists. The number of tests increased by 10-year age categories up to the age-group of 80-90 years. The number of INR measurements increased from 169,636 in 2011 to 176,184 in 2012, but then decreased slightly to 162,597 in 2013 and 164,427 in 2014. Mean coefficient of variation of INR was 19.0%, and mean TTR was 29.0%. TTR was higher in women than in men (31% vs. 18%), in older than in younger patients (19.1% at 40 years and 38.6% at 100 years) and in patients with arrhythmias than in those with deep vein thrombosis/pulmonary embolism (44.4% versus 19.4%) (p < 10 VKAs are still frequently prescribed in this era of direct oral anticoagulants. The low TTR cannot be explained by inadequate INR monitoring.
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Vitamin K
12001-79-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212-1217Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Konstantinides SV , Torbicki A , Agnelli G , et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(3033-69):3069a-3069k.
Kirchhof P , Benussi S , Kotecha D , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
Holbrook A , Schulman S , Witt DM , et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S-e184S.
Authors/Task Force Members, Vahanian A , Alfieri O , et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;2012(33):2451-2496.
Jourdi G , Mansour A , Vayne C , et al. Anticoagulation therapy in France: state-of-the-art in 2020. Ann Blood. 2020;5:3.
Maura G , Billionnet C , Drouin J , Weill A , Neumann A , Pariente A . Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open. 2019;9:e026645.
Lane DA , Lip GYH . Maintaining therapeutic anticoagulation: the importance of keeping “within range”. Chest. 2007;131:1277-1279.
Hindricks G , Potpara T , Dagres N , et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498.
Connolly SJ , Pogue J , Eikelboom J , et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
Gallagher AM , Setakis E , Plumb JM , Clemens A , van Staa T-P . Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968-977.
De Caterina R , Husted S , Wallentin L , et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:569-579.
Lader E , Martin N , Cohen G , et al. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? J Clin Pharm Ther. 2012;37:375-377.
Vestergaard AS , Skjøth F , Larsen TB , Ehlers LH . The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One. Public Library of Science. 2017;12(11):e0188482.
Singer DE , Hellkamp AS , Piccini JP , et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1), e000067.
Roski J , Bo-Linn GW , Andrews TA . Creating value in health care through big data: opportunities and policy implications. Health Aff. 2014;33:1115-1122.
Dubois N , Garnier N , Meune C . Potential of big data analytics in the French in vitro diagnostics market. Ann Biol Clin. 2017;75:683-685.
Sorbets E , Goudot F-X , Garnier N , et al. Over 70 million blood analyses in nearly 600,000 French adults between 2010 and 2015 methodology of the rubidium big data study. J Clin Trial Cardiol. 2018;5:1-6.
Rosendaal FR , Cannegieter SC , van der Meer FJ , Briët E . A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239.
Charlemagne A , Blacher J , Cohen A , et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis. 2011;104:115-124.
Huiart L , Ferdynus C , Renoux C , et al. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018;8:e018180.
Dybdahl T , Andersen M , Søndergaard J , Kragstrup J , Kristiansen IS . Does the early adopter of drugs exist? A population-based study of general practitioners’ prescribing of new drugs. Eur J Clin Pharmacol. 2005;61:75.
Zhang Y , Méndez SJ , Scott A . Factors affecting general practitioners’ decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data. BMC Health Serv Res. 2019;19:94.
Reiffel JA . Time in the therapeutic range for patients taking warfarin in clinical trials: useful, but also misleading, misused, and overinterpreted. Circulation. 2017;135:1475-1477.
Witt DM , Delate T , Clark NP , et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010;8:744-749.
Apostolakis S , Sullivan RM , Olshansky B , Lip GYH . Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013;144:1555-1563.
Rose AJ , Hylek EM , Ozonoff A , Ash AS , Reisman JI , Berlowitz DR . Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8:2182-2191.
Ansell J , Hollowell J , Pengo V , Martinez-Brotons F , Caro J , Drouet L . Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007;23:83-91.
Rudd KM , Dier JG . Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30:330-338.
Björck F , Sandén P , Renlund H , Svensson PJ , Själander A . Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thromb Res. 2015;136:216-220.
Penning-van Beest FJA , Geleijnse JM , van Meegen E , Vermeer C , Rosendaal FR , Stricker BHC . Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol. 2002;55:411-417.
Rombouts EK , Rosendaal FR , van der Meer FJM . Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost. 2009;101:552-556.
Ansell J , Hirsh J , Hylek E , Jacobson A , Crowther M , Palareti G . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S-198S.
de Assis MC , Rabelo ER , Ávila CW , Polanczyk CA , Rohde LE . Improved oral anticoagulation after a dietary vitamin K-guided strategy. Circulation. American Heart Association. 2009;120:1115-1122.
January CT , Wann LS , Alpert JS , et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-267.
ANSM. Rapport sur les anticoagulants en France en 2014 : état des lieux, synthèse et surveillance. [Internet]. 2014 [cited 2021 May 26]. Available from: https://www.portailvasculaire.fr/sites/default/files/docs/ansm-rapport_nacos-avril_2014-2_0.pdf
Samsa GP , Matchar DB , Goldstein LB , et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160:967-973.
Devereaux PJ , Anderson DR , Gardner MJ , et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218-1222.
Bénard-Laribière A , Miremont-Salamé G , Pérault-Pochat M-C , Noize P , Haramburu F . Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. Fundam Clin Pharmacol. 2015;29:106-111.
Barnes GD , Nallamothu BK , Sales AE , Froehlich JB . Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9:182-185.
Kristoffersen A-H , Thue G , Ajzner E , et al. Interpretation and management of INR results: a case history based survey in 13 countries. Thromb Res. 2012;130:309-315.
Azarnoush K , Camilleri L , Aublet-Cuvelier B , et al. Results of the first randomized French study evaluating self-testing of the International Normalized Ratio. J Heart Valve Dis. 2011;20:518-525.